HM Payson & Co’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.01M | Hold |
12,837
| – | – | 0.03% | 165 |
|
|
2026
Q1 | $1.96M | Sell |
12,837
-223
| -2% | -$34.2K | 0.03% | 164 |
|
|
2025
Q4 | $1.8M | Sell |
13,060
-202
| -2% | -$26.5K | 0.03% | 165 |
|
|
2025
Q3 | $1.7M | Buy |
13,262
+10,000
| +307% | +$1.22M | 0.02% | 164 |
|
|
2025
Q2 | $395K | Sell |
3,262
-850
| -21% | -$95.8K | 0.01% | 310 |
|
|
2025
Q1 | $458K | Buy |
4,112
+50
| +1% | +$5.32K | 0.01% | 293 |
|
|
2024
Q4 | $395K | Buy |
4,062
+899
| +28% | +$95.9K | 0.01% | 310 |
|
|
2024
Q3 | $364K | Buy |
3,163
+358
| +13% | +$40.6K | 0.01% | 328 |
|
|
2024
Q2 | $299K | Hold |
2,805
| – | – | 0.01% | 346 |
|
|
2024
Q1 | $271K | Hold |
2,805
| – | – | 0.01% | 350 |
|
|
2023
Q4 | $283K | Sell |
2,805
-150
| -5% | -$14.5K | 0.01% | 337 |
|
|
2023
Q3 | $301K | Buy |
2,955
+525
| +22% | +$53.3K | 0.01% | 321 |
|
|
2023
Q2 | $245K | Buy |
2,430
+25
| +1% | +$2.5K | 0.01% | 342 |
|
|
2023
Q1 | $221K | Sell |
2,405
-731
| -23% | -$63.8K | 0.01% | 354 |
|
|
2022
Q4 | $284K | Sell |
3,136
-1,553
| -33% | -$131K | 0.01% | 317 |
|
|
2022
Q3 | $356K | Buy |
4,689
+1,295
| +38% | +$107K | 0.01% | 281 |
|
|
2022
Q2 | $287K | Sell |
3,394
-245
| -7% | -$21.5K | 0.01% | 313 |
|
|
2022
Q1 | $319K | Buy |
3,639
+210
| +6% | +$18.2K | 0.01% | 325 |
|
|
2021
Q4 | $300K | Buy |
3,429
+402
| +13% | +$33.4K | 0.01% | 350 |
|
|
2021
Q3 | $248K | Buy |
3,027
+28
| +0.9% | +$2.52K | 0.01% | 365 |
|
|
2021
Q2 | $274K | Sell |
2,999
-187
| -6% | -$16.7K | 0.01% | 353 |
|
|
2021
Q1 | $272K | Buy |
3,186
+573
| +22% | +$51.4K | 0.01% | 348 |
|
|
2020
Q4 | $247K | Sell |
2,613
-560
| -18% | -$48.9K | 0.01% | 357 |
|
|
2020
Q3 | $276K | Buy |
3,173
+297
| +10% | +$25.7K | 0.01% | 317 |
|
|
2020
Q2 | $251K | Hold |
2,876
| – | – | 0.01% | 310 |
|
|
2020
Q1 | $237K | Sell |
2,876
-200
| -7% | -$17.8K | 0.01% | 295 |
|
|
2019
Q4 | $291K | Sell |
3,076
-5,846
| -66% | -$525K | 0.01% | 331 |
|
|
2019
Q3 | $775K | Sell |
8,922
-585
| -6% | -$52.5K | 0.03% | 218 |
|
|
2019
Q2 | $868K | Sell |
9,507
-2,012
| -17% | -$170K | 0.03% | 211 |
|
|
2019
Q1 | $992K | Buy |
+11,519
| New | +$925K | 0.04% | 171 |
|
|
2018
Q4 | – | Sell |
-10,649
| Closed | -$822K | – | 266 |
|
|
2018
Q3 | $822K | Sell |
10,649
-167
| -2% | -$12.3K | 0.04% | 192 |
|
|
2018
Q2 | $732K | Sell |
10,816
-45
| -0.4% | -$3.1K | 0.03% | 203 |
|
|
2018
Q1 | $787K | Sell |
10,861
-192
| -2% | -$14.6K | 0.03% | 195 |
|
|
2017
Q4 | $831K | Buy |
11,053
+248
| +2% | +$18.7K | 0.03% | 201 |
|
|
2017
Q3 | $831K | Sell |
10,805
-558
| -5% | -$42.1K | 0.04% | 193 |
|
|
2017
Q2 | $850K | Sell |
11,363
-69
| -0.6% | -$4.89K | 0.04% | 195 |
|
|
2017
Q1 | $761K | Hold |
11,432
| – | – | 0.03% | 201 |
|
|
2016
Q4 | $746K | Hold |
11,432
| – | – | 0.04% | 203 |
|
|
2016
Q3 | $809K | Sell |
11,432
-632
| -5% | -$46.1K | 0.04% | 195 |
|
|
2016
Q2 | $892K | Sell |
12,064
-410
| -3% | -$28.3K | 0.04% | 185 |
|
|
2016
Q1 | $810K | Buy |
12,474
+141
| +1% | +$9.59K | 0.04% | 188 |
|
|
2015
Q4 | $951K | Buy |
12,333
+961
| +8% | +$76.3K | 0.05% | 183 |
|
|
2015
Q3 | $937K | Hold |
11,372
| – | – | 0.05% | 174 |
|
|
2015
Q2 | $1M | Buy |
11,372
+123
| +1% | +$11.3K | 0.05% | 178 |
|
|
2015
Q1 | $994K | Sell |
11,249
-225
| -2% | -$20K | 0.05% | 174 |
|
|
2014
Q4 | $953K | Buy |
11,474
+765
| +7% | +$63.4K | 0.05% | 175 |
|
|
2014
Q3 | $903K | Buy |
10,709
+19
| +0.2% | +$1.54K | 0.05% | 180 |
|
|
2014
Q2 | $867K | Buy |
10,690
+268
| +3% | +$21.1K | 0.04% | 175 |
|
|
2014
Q1 | $794K | Buy |
10,422
+137
| +1% | +$9.98K | 0.04% | 176 |
|
|
2013
Q4 | $741K | Sell |
10,285
-22
| -0.2% | -$1.53K | 0.04% | 184 |
|
|
2013
Q3 | $708K | Buy |
10,307
+52
| +0.5% | +$3.44K | 0.04% | 186 |
|
|
2013
Q2 | $650K | Buy |
+10,255
| New | +$667K | 0.04% | 184 |
|
Other funds holding NVS
HM Payson & Co's NVS Position: Q2 2026 in Review
HM Payson & Co held its Novartis (NVS) position steady in Q2 2026 at 12,837 shares worth $2.01M. The position accounts for 0.03% of the portfolio, ranked #165.
HM Payson & Co first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. 1,612 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- HM Payson & Co held 12,837 shares of Novartis worth $2.01M as of Q2 2026.
- HM Payson & Co left its Novartis share count unchanged in Q2 2026.
- Novartis made up 0.03% of HM Payson & Co's portfolio in Q2 2026, its #165 holding.
- HM Payson & Co first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
- 1,612 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.